Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GEN3018 · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| GEN3018 | EXPERIMENTAL | Participants will receive escalating doses of GEN3018 in Part 1 (Dose Escalation). In Part 2 (Dose Refinement), additional participants may be enrolled to evaluate the safety and preliminary efficacy data of the recommended Part 2 dose(s) as determined from the Part 1 Dose Escalation. |
| Name | Type | Description |
|---|---|---|
| GEN3018 | BIOLOGICAL | Intravenous (IV) infusion. |
Key Inclusion Criteria: All Participants: * Be at least 18 years of age at the time of signing informed consent form (ICF). * Participant's life expectancy at screening is judged to be at least 3 months. * Must have fresh bone marrow samples collected at screening. * Bone marrow (BM) blasts ≥ 5% a...
GEN3018 is an investigational monoclonal antibody being developed for relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
GEN3018 is being developed by Genmab A/S, a biopharmaceutical company listed on the Nasdaq under the ticker GMAB. The company is conducting a first-in-human trial of the drug in patients with relapsed or refractory AML or higher-risk MDS.
GEN3018 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved for any use. The ongoing Phase 1 trial is recruiting patients to evaluate the drug's safety and tolerability.
GEN3018 is being studied in a single Phase 1 trial with the identifier NCT07384715. This first-in-human study is recruiting patients with relapsed or refractory acute myeloid leukemia or higher-risk myelodysplastic syndrome, with an enrollment target of 78 participants.
GEN3018 is the sole name provided for this investigational monoclonal antibody. No alternative names or aliases have been associated with this drug in the available information.